#USA #Bio-Techne #Monod Bio #NovoBody Duo #Minneapolis, Seattle

Bio-Techne Partners with Monod Bio for AI-Designed Protein Innovation

In a significant move for the biotechnology sector, Bio-Techne Corporation (NASDAQ: TECH), a leader in life sciences tools, has secured a licensing agreement with Monod Bio, a Seattle-based biotech firm. This collaboration will bring forth new AI-designed protein innovations, particularly the NovoBody™ Duo molecules, a novel class of bispecific binding proteins. This agreement not only highlights the cutting-edge fusion of artificial intelligence (AI) and biotechnology but also reinforces Bio-Techne’s commitment to advancing scientific research and diagnostics.

The Innovative NovoBody Duo Molecules

The NovoBody Duo molecules represent a breakthrough in the design of bispecific binding proteins. Unlike traditional antibodies that may take longer to develop and can be costly, these newly licensed proteins are compact, tunable, and can be engineered swiftly. This allows researchers to adapt the proteins for various multi-specific binding applications quickly, making them an ideal resource for next-generation diagnostics and therapeutic developments.

Will Geist, President of the Protein Sciences Segment at Bio-Techne, emphasized the impact of this partnership: "This partnership marks an exciting step forward in how we are using artificial intelligence to advance scientific progress. NovoBody Duo molecules extend our portfolio with innovative AI-powered designs and state-of-the-art customization, stability, and performance. They enable customers to target complex biology with greater precision and accelerate the development of better therapies."

Alfredo Quijano Rubio, Chief Scientific Officer of Monod Bio, elaborated further on the advantages these molecules provide. He stated that they can be developed quickly and cost-effectively compared to traditional antibodies, enhancing their potential in contemporary research.

A Strategic Alignment for Growth

This agreement not only bolsters Bio-Techne's recombinant protein offerings but also aligns neatly with the company’s strategic growth initiatives, particularly in precision medicine. The deal is set against the backdrop of a broader trend in the healthcare sector, where AI and machine learning are transforming how biological research is conducted. Daniel Silva Manzano, CEO of Monod Bio, expressed enthusiasm about the synergy between the two companies’ missions: "We are thrilled to partner with Bio-Techne, whose commitment to innovation and scientific excellence aligns perfectly with our mission. This collaboration validates our platform and accelerates the integration of Monod's AI-designed proteins into mainstream life sciences."

The partnership supports Bio-Techne's aim to discover new biological insights and to advance the development of new therapies. It places the company at the forefront of AI-driven innovation in the life sciences, highlighting the potential this technology holds for transforming healthcare and research.

About Bio-Techne

Bio-Techne Corporation is a global life sciences company known for providing innovative tools and bioactive reagents that serve the research and clinical diagnostics communities. With an extensive product portfolio, the company plays a crucial role in enabling scientific exploration of complex biological processes and advancing drug discovery. In fiscal 2025, Bio-Techne reported over $1.2 billion in net sales and employs approximately 3,100 individuals worldwide. For more information, visit Bio-Techne's official website.

About Monod Bio

Monod Bio operates out of Seattle and originated from the David Baker Lab at the University of Washington, focusing on de novo protein design. The company specializes in creating novel protein binders and biosensors, addressing unmet needs in the research and diagnostics fields. Their unique approach, combined with partnerships with leading organizations, positions Monod Bio at the cutting edge of next-generation life science products. For additional insights, check out Monod Bio's website.